# Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia

> **NCT00002925** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 410 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** ara-C
- **DRUG:** Daunorubicin
- **DRUG:** Etoposide
- **DRUG:** PSC-833
- **BIOLOGICAL:** Aldesleukin

## Key facts

- **NCT ID:** NCT00002925
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-02
- **Primary completion:** 2003-11
- **Final completion:** 2010-06
- **Target enrollment:** 410 (ACTUAL)
- **Last updated:** 2012-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002925, "Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00002925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*